Biotechnology company with a proprietary computational and machine learning platform
Oxford Drug Design has raised €2.6M across 1 funding round from 4 investors, most recently a round in May 2022. Based in Oxford, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-05-19 | Other |
| €2.6M |
| ACF investors,Meltwind Advisory,o2h Ventures,R42 Group |
| View deal → |
